Biocompatible smart micro/nanorobots for active gastrointestinal tract drug delivery

作者全名："Zhang, Baozhen; Zhu, Lizhen; Pan, Hong; Cai, Lintao"

作者地址："[Zhang, Baozhen; Zhu, Lizhen; Pan, Hong; Cai, Lintao] Shenzhen Inst Adv Technol, Chinese Acad Sci CAS, Guangdong Key Lab Nanomed, HK Joint Lab Biomat, Shenzhen, Peoples R China; [Zhang, Baozhen] Chongqing Med Univ, Dept Obstet & Gynecol, Women & Childrens Hosp, Chongqing, Peoples R China"

通信作者："Pan, H; Cai, LT (通讯作者)，Shenzhen Inst Adv Technol, Chinese Acad Sci CAS, Guangdong Key Lab Nanomed, HK Joint Lab Biomat, Shenzhen, Peoples R China."

来源：EXPERT OPINION ON DRUG DELIVERY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001087807000001

JCR分区：Q1

影响因子：5

年份：2023

卷号：20

期号：10

开始页：1427

结束页：1441

文献类型：Review

关键词：Gastrointestinal tract; physiological barriers; micro/nanorobots; drug delivery; precision therapy

摘要："IntroductionOral delivery is the most commonly used route of drug administration owing to good patient compliance. However, the gastrointestinal (GI) tract contains multiple physiological barriers that limit the absorption efficiency of conventional passive delivery systems resulting in a low drug concentration reaching the diseased sites. Micro/nanorobots can convert energy to self-propulsive force, providing a novel platform to actively overcome GI tract barriers for noninvasive drug delivery and treatment.Areas coveredIn this review, we first describe the microenvironments and barriers in the different compartments of the GI tract. Afterward, the applications of micro/nanorobots to overcome GI tract barriers for active drug delivery are highlighted and discussed. Finally, we summarize and discuss the challenges and future prospects of micro/nanorobots for further clinical applications.Expert opinionMicro/nanorobots with the ability to autonomously propel themselves and to load, transport, and release payloads on demand are ideal carriers for active oral drug delivery. Although there are many challenges to be addressed, micro/nanorobots have great potential to introduce a new era of drug delivery for precision therapy."

基金机构："National Key Research and Development Program of China [2022YFC2402400]; National Natural Science Foundation of China [82302374, 81971749, 82303768]; Guangdong Provincial Key Area RD Program [2020B1111540001]; Natural Science Foundation of Guangdong Province [2022A1515010780]; Shenzhen Science and Technology Program [JCYJ20200109114616534, JCYJ20210324101807020]; Guangdong Basic and Applied Basic Research Foundation [2022A1515111168]"

基金资助正文："This work was supported by the National Key Research and Development Program of China (2022YFC2402400), the National Natural Science Foundation of China (82302374, 81971749, 82303768), Guangdong Provincial Key Area R&D Program (2020B1111540001), the Natural Science Foundation of Guangdong Province (2022A1515010780), Shenzhen Science and Technology Program (JCYJ20200109114616534, JCYJ20210324101807020), and Guangdong Basic and Applied Basic Research Foundation (2022A1515111168)."